Detailed View
TBPH - Theravance Biopharma, Inc.
Latest filing: 2026-03-31 | Reporting: gaap
Market Cap
850,109,056
Adj EBIT (TTM)
37,444,500
Enterprise Value
562,008,056
Last Price
16.49
Earnings Yield
6.66%
Return on Capital
8.50%
Capital
440,538,000
1Y Price Chart
Last Price: -
1Y Change: -
Company Summary
Loading summary...
| endDate | formType | fiscalYear | Revenue | OperatingIncomeLoss |
|---|---|---|---|---|
| 2026-03-31 | 10-Q | 2026 | 17,699,000 | -9,483,000 |
| 2025-12-31 | 10-K (Q4 derived) | 2025 | -15,682,000 | 43,626,000 |
| 2025-09-30 | 10-Q | 2025 | 19,990,000 | -6,455,000 |
| 2025-06-30 | 10-Q | 2025 | 26,195,000 | -2,725,000 |
| 2025-03-31 | 10-Q | 2025 | 15,388,000 | -14,434,000 |
| 2024-12-31 | 10-K (Q4 derived) | 2024 | -26,873,000 | 28,549,000 |
| 2024-09-30 | 10-Q | 2024 | 16,868,000 | -10,837,000 |
| 2024-06-30 | 10-Q | 2024 | 14,256,000 | -15,705,000 |
Notice something wrong?
Submit a quick report with a snapshot of the values you are seeing.